AIM: Nanoformulated antiretroviral therapy can improve drug compliance for people infected with HIV. Additional benefits would include specific drug deliveries to viral reservoirs and reduction in systemic toxicities. METHODS: In this article, we describe mechanisms of crystalline antiretroviral nanoparticle (NP) uptake, intracellular trafficking and release in human monocyte-derived macrophages. RESULTS: Following clathrin-dependent endocytosis NPs bypassed lysosomal degradation by sorting from early endosomes to recycling endosome pathways. Disruption of this pathway by siRNAs or brefeldin-A impaired particle release. Proteomic and biological analysis demonstrated that particle recycling was primarily Rab11 regulated. Particles were released intact and retained complete antiretroviral efficacy. CONCLUSION: These results suggest possible pathways of subcellular transport of antiretroviral nanoformulations that preserve both particle integrity and antiretroviral activities demonstrating the potential utility of this approach for targeted drug delivery.
AIM: Nanoformulated antiretroviral therapy can improve drug compliance for people infected with HIV. Additional benefits would include specific drug deliveries to viral reservoirs and reduction in systemic toxicities. METHODS: In this article, we describe mechanisms of crystalline antiretroviral nanoparticle (NP) uptake, intracellular trafficking and release in human monocyte-derived macrophages. RESULTS: Following clathrin-dependent endocytosis NPs bypassed lysosomal degradation by sorting from early endosomes to recycling endosome pathways. Disruption of this pathway by siRNAs or brefeldin-A impaired particle release. Proteomic and biological analysis demonstrated that particle recycling was primarily Rab11 regulated. Particles were released intact and retained complete antiretroviral efficacy. CONCLUSION: These results suggest possible pathways of subcellular transport of antiretroviral nanoformulations that preserve both particle integrity and antiretroviral activities demonstrating the potential utility of this approach for targeted drug delivery.
Authors: Santhi Gorantla; Huanyu Dou; Michael Boska; Chris J Destache; Jay Nelson; Larisa Poluektova; Barett E Rabinow; Howard E Gendelman; R Lee Mosley Journal: J Leukoc Biol Date: 2006-08-14 Impact factor: 4.962
Authors: Huanyu Dou; Justin Morehead; Christopher J Destache; Jeffrey D Kingsley; Lyudmila Shlyakhtenko; You Zhou; Mahesh Chaubal; Jane Werling; James Kipp; Barrett E Rabinow; Howard E Gendelman Journal: Virology Date: 2006-09-25 Impact factor: 3.616
Authors: Eric Schonteich; Gayle M Wilson; Jemima Burden; Colin R Hopkins; Keith Anderson; James R Goldenring; Rytis Prekeris Journal: J Cell Sci Date: 2008-10-28 Impact factor: 5.285
Authors: Yutong Liu; Mariano G Uberti; Huanyu Dou; Rebecca Banerjee; Cassi B Grotepas; David K Stone; Barrett E Rabinow; Howard E Gendelman; Michael D Boska Journal: J Neuroimmunol Date: 2008-07-24 Impact factor: 3.478
Authors: Jessica L Reynolds; Wing Cheung Law; Supriya D Mahajan; Ravikumar Aalinkeel; Bindukumar Nair; Donald E Sykes; Ken-Tye Yong; Rui Hui; Paras N Prasad; Stanley A Schwartz Journal: J Neuroimmune Pharmacol Date: 2012-06-12 Impact factor: 4.147
Authors: Adam H Marblestone; Bradley M Zamft; Yael G Maguire; Mikhail G Shapiro; Thaddeus R Cybulski; Joshua I Glaser; Dario Amodei; P Benjamin Stranges; Reza Kalhor; David A Dalrymple; Dongjin Seo; Elad Alon; Michel M Maharbiz; Jose M Carmena; Jan M Rabaey; Edward S Boyden; George M Church; Konrad P Kording Journal: Front Comput Neurosci Date: 2013-10-21 Impact factor: 2.380
Authors: Andrea L Martinez-Skinner; Ram S Veerubhotla; Han Liu; Huangui Xiong; Fang Yu; JoEllyn M McMillan; Howard E Gendelman Journal: J Proteome Res Date: 2013-04-17 Impact factor: 4.466
Authors: Upal Roy; JoEllyn McMillan; Yazen Alnouti; Nagsen Gautum; Nathan Smith; Shantanu Balkundi; Prasanta Dash; Santhi Gorantla; Andrea Martinez-Skinner; Jane Meza; Georgette Kanmogne; Susan Swindells; Samuel M Cohen; R Lee Mosley; Larisa Poluektova; Howard E Gendelman Journal: J Infect Dis Date: 2012-07-17 Impact factor: 5.226
Authors: Gang Zhang; Dongwei Guo; Prasanta K Dash; Mariluz Araínga; Jayme L Wiederin; Nicole A Haverland; Jaclyn Knibbe-Hollinger; Andrea Martinez-Skinner; Pawel Ciborowski; Val S Goodfellow; Tadeusz A Wysocki; Beata J Wysocki; Larisa Y Poluektova; Xin-Ming Liu; JoEllyn M McMillan; Santhi Gorantla; Harris A Gelbard; Howard E Gendelman Journal: Nanomedicine Date: 2015-10-22 Impact factor: 5.307
Authors: Susanna L Lamers; Gary B Fogel; Elyse J Singer; Marco Salemi; David J Nolan; Leanne C Huysentruyt; Michael S McGrath Journal: Int Rev Immunol Date: 2012-12 Impact factor: 5.311